Cargando…

B7-H4 Immune Checkpoint Protein Affects Viability and Targeted Therapy of Renal Cancer Cells

Targeted therapy in combination with immune checkpoint inhibitors has been recently implemented in advanced or metastatic renal cancer treatment. However, many treated patients either do not respond or develop resistance to therapy, making alternative immune checkpoint-based immunotherapies of poten...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emaldi, Maite, Nunes-Xavier, Caroline E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104196/ https://www.ncbi.nlm.nih.gov/pubmed/35563753 http://dx.doi.org/10.3390/cells11091448

Ejemplares similares

Hopes on immunotherapy targeting B7-H3 in neuroblastoma
por: Pulido, Rafael, et al.
Publicado: (2022)

The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma
por: Nunes-Xavier, Caroline E., et al.
Publicado: (2023)

Author Correction: The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma
por: Nunes‑Xavier, Caroline E., et al.
Publicado: (2023)

Pediatric medulloblastoma express immune checkpoint B7-H3
por: Li, S., et al.
Publicado: (2022)

Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer
por: Bazhin, Alexandr V., et al.
Publicado: (2022)

Protein Tyrosine Phosphatases in Neuroblastoma: Emerging Roles as Biomarkers and Therapeutic Targets
por: Nunes-Xavier, Caroline E., et al.
Publicado: (2021)

Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy
por: Zhao, Binghao, et al.
Publicado: (2022)

B7-H3, a checkpoint molecule, as a target for cancer immunotherapy
por: Yang, Shuo, et al.
Publicado: (2020)

Synthetic viability induces resistance to immune checkpoint inhibitors in cancer cells
por: Liu, Mingyue, et al.
Publicado: (2023)

New frontiers in immune checkpoint B7-H3 (CD276) research and drug development
por: Getu, Ayechew Adera, et al.
Publicado: (2023)

Immune checkpoint: The novel target for antitumor therapy
por: Jiang, Xianghu, et al.
Publicado: (2019)

Simultaneous targeting of mitochondrial metabolism and immune checkpoints as a new strategy for renal cancer therapy
por: Stemberkova‐Hubackova, Sona, et al.
Publicado: (2022)

Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer
por: Nunes-Xavier, Caroline E., et al.
Publicado: (2022)

MEDB-76. Evaluating the B7-H3 checkpoint in Medulloblastoma
por: Moziak, Kirsten, et al.
Publicado: (2022)

The immune checkpoint B7-H3 (CD276) regulates adipocyte progenitor metabolism and obesity development
por: Picarda, Elodie, et al.
Publicado: (2022)

SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models
por: Gray, Elizabeth, et al.
Publicado: (2023)

The co-inhibitory immune checkpoint proteins B7-H1(PD-L1) and B7-H4 in high grade glioma: From bench to bedside
por: Qi, Ying, et al.
Publicado: (2023)

Targeting the “PVR–TIGIT axis” with immune checkpoint therapies
por: Gorvel, Laurent, et al.
Publicado: (2020)

Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes
por: Qi, Yangzhi, et al.
Publicado: (2020)

Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy
por: Parosanu, Andreea, et al.
Publicado: (2022)

Expression of a novel immune checkpoint B7-H6 ligand in human small cell lung cancer
por: Zhang, Xiuqin, et al.
Publicado: (2020)

Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation
por: Segovia, Mercedes, et al.
Publicado: (2019)

A decade of immune-checkpoint inhibitors in cancer therapy
por: Robert, Caroline
Publicado: (2020)

Therapy to target renal cell carcinoma using (131)I-labeled B7-H3 monoclonal antibody
por: Wang, Gongcheng, et al.
Publicado: (2016)

Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma
por: Liu, Ziyu, et al.
Publicado: (2019)

Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy
por: Huang, Jau-Ling, et al.
Publicado: (2022)

Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma
por: Wirsching, Hans-Georg, et al.
Publicado: (2021)

Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy
por: Li, Haohao, et al.
Publicado: (2022)

Increased H(+) efflux is sufficient to induce dysplasia and necessary for viability with oncogene expression
por: Grillo-Hill, Bree K, et al.
Publicado: (2015)

Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies
por: Chen, Miaoqin, et al.
Publicado: (2020)

PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy
por: Rolfes, Verena, et al.
Publicado: (2018)

Sex — a potential factor affecting immune checkpoint inhibitor therapy for cancers
por: Hu, Wang, et al.
Publicado: (2022)

Immune checkpoint inhibitors in renal cell carcinoma
por: Ross, Kirsty, et al.
Publicado: (2017)

Impact of primary resistance to front-line targeted therapy in metastatic renal cell carcinoma on subsequent immune-checkpoint-inhibition
por: Börner, J. H., et al.
Publicado: (2023)

Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?
por: Haist, Maximilian, et al.
Publicado: (2023)

Imaging of Clear Cell Renal Carcinoma with Immune Checkpoint Targeting Aptamer-Based Probe
por: Malicki, Stanisław, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
por: Herrmann, Sandra M., et al.
Publicado: (2020)

Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I(−/−) iPSCs for β cell replacement
por: Chimienti, Raniero, et al.
Publicado: (2022)

The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy
por: John, Peter, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review
por: Nunes Filho, Paulo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mn8u6ovkoejnctro2lpih3hej1